Medpage Today on MSN7d
Pembrolizumab-Olaparib Boosts PFS in Non-BRCA Ovarian Cancer
A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...
CURE3d
First Patent Dosed With Pocenbrodib in Trial for Metastatic Prostate Cancer
First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...
pharmaphorum3y
AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy
AZ and Merck said that the approval makes Lynparza (olaparib) the only PARP inhibitor to have shown an improvement in overall survival when used in this setting, ahead of rivals like Clovis ...
pharmaphorum1mon
Lynparza first PARP drug to show promise in breast cancer
Results from a phase 3 trial presented today showed that patients treated with Lynparza (olaparib) had a 42% reduction in risk of their disease worsening or death in for patients with HER2 ...
National Institute for Health and Care Excellence1mon
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
Olaparib (Lynparza, AstraZeneca) is indicated as 'monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative locally advanced or metastatic breast cancer.
Pharm Exec14d
Lynparza and Breast Cancer: Study Finds Reduced Recurrence Risk in HR-Positive Patients
Full Interview Summary: The six-year follow-up data from the OlympiA trial demonstrated a 28% reduction in the risk of death with Lynparza (olaparib) for patients with germline BRCA-mutated, ...
Hosted on MSN10mon
DCGI orders withdrawal of Olaparib for select cancer patients over safety concerns
New Delhi: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse ...